CD274 and non-small cell lung carcinoma: In the present study, significantly improved OS and PFS were observed in patients with NSCLC with a low or high PD‐L1 expression level, but not in those with intermediate PD‐L1 TPS with significant HR differences among the three subgroups of PD‐L1 status.